No data to show
XNAS
KRYS
Market cap3.82bUSD
May 19, Last price
132.29USD
1D
1.29%
1Q
-15.57%
IPO
1,190.63%
Name
Krystal Biotech Inc
Chart & Performance
P/E
42.88
P/S
13.16
EPS
3.09
Div Yield, %
—
Shrs. gr., 5y
13.34%
Rev. gr., 5y
118.12%
Revenues
291m
+473.02%
Net income
89m
+715.58%
CFO
123m
P
Earnings
Aug 04, 2025
Profile
Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing KB105 that is in Phase I/II clinical study for treating patients with deficient autosomal recessive congenital ichthyosis; KB301, which is in Phase I/II clinical stage for treating wrinkles and other presentations of aged or damaged skin; KB407 that is in preclinical stage for cystic fibrosis; and KB104, which is in preclinical stage for netherton syndrome. Its discovery stage product candidates include KB5xx for treating chronic skin diseases, KB3xx to treat aesthetic skin conditions, and KB3xx product. Krystal Biotech, Inc. was founded in 2015 and is headquartered in Pittsburgh, Pennsylvania.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | |||||||||
Revenues | 290,515 473.02% | 50,699 | |||||||
Cost of revenue | 73,634 | 49,525 | 124,251 | ||||||
Unusual Expense (Income) | |||||||||
NOPBT | 216,881 | 1,174 | (124,251) | ||||||
NOPBT Margin | 74.65% | 2.32% | |||||||
Operating Taxes | 6,197 | 1,965 | 34,048 | ||||||
Tax Rate | 2.86% | 167.38% | |||||||
NOPAT | 210,684 | (791) | (158,299) | ||||||
Net income | 89,159 715.58% | 10,932 -107.81% | (139,975) 101.20% | ||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | 203,499 | 35,996 | |||||||
BB yield | -5.91% | -1.78% | |||||||
| Debt | |||||||||
Debt current | 1,217 | 2,948 | 1,561 | ||||||
Long-term debt | 13,305 | 14,714 | 16,305 | ||||||
Deferred revenue | |||||||||
Other long-term liabilities | 1,419 | ||||||||
Net debt | (735,109) | (576,470) | (365,926) | ||||||
| Cash flow | |||||||||
Cash from operating activities | 123,420 | (88,804) | (100,569) | ||||||
CAPEX | (4,238) | (11,799) | (52,979) | ||||||
Cash from investing activities | (163,439) | 82,638 | (114,083) | ||||||
Cash from financing activities | 27,014 | 202,750 | 35,347 | ||||||
FCF | 197,295 | (27,162) | (208,442) | ||||||
| Balance | |||||||||
Cash | 597,517 | 532,178 | 379,171 | ||||||
Long term investments | 152,114 | 61,954 | 4,621 | ||||||
Excess cash | 735,105 | 591,597 | 383,792 | ||||||
Stockholders' equity | (180,858) | (269,189) | (281,487) | ||||||
Invested Capital | 1,135,918 | 1,057,398 | 812,608 | ||||||
ROIC | 19.21% | ||||||||
ROCE | 22.71% | 0.15% | |||||||
| EV | |||||||||
Common stock shares outstanding | 29,740 | 27,752 | 25,492 | ||||||
Price | 156.66 26.28% | 124.06 56.60% | 79.22 13.25% | ||||||
Market cap | 4,659,068 35.32% | 3,442,889 70.49% | 2,019,454 30.06% | ||||||
EV | 3,923,959 | 2,866,419 | 1,653,528 | ||||||
EBITDA | 223,595 | 6,181 | (120,196) | ||||||
EV/EBITDA | 17.55 | 463.75 | |||||||
Interest | 5,221 | ||||||||
Interest/NOPBT | |||||||||